{"filing":{"accession_number":"0001193125-26-346919","cik":"0002096997","ticker":"KLRA","company_name":"Kailera Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"ck0002096997-20260812.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2096997/000119312526346919/ck0002096997-20260812.htm"},"events":[{"id":27257,"run_id":24828,"accession_number":"0001193125-26-346919","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release disclosing Kailera's financial results for Q2 2026 (quarter ended June 30, 2026), filed on August 12, 2026. The press release reports R\u0026D expenses of $101.1 million, G\u0026A expenses of $20.3 million, and a net loss of $111.3 million for the quarter, along with cash position of $1,171.8 million. The disclosure includes both financial results and material business updates regarding clinical trial progress and executive appointments, which are typical components of a quarterly earnings release.","company_name":"Kailera Therapeutics, Inc.","ticker":"KLRA","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28704,"accession_number":"0001193125-26-346919","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Kailera's financial results for Q2 2026 (quarter ended June 30, 2026), filed on August 12, 2026. The press release reports R\u0026D expenses of $101.1 million, G\u0026A expenses of $20.3 million, and a net loss of $111.3 million for the quarter, along with cash position of $1,171.8 million. The disclosure includes both financial results and material business updates regarding clinical trial progress and executive appointments, which are typical components of a quarterly earnings release.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:28:03.132497+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28704,"accession_number":"0001193125-26-346919","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Kailera's financial results for Q2 2026 (quarter ended June 30, 2026), filed on August 12, 2026. The press release reports R\u0026D expenses of $101.1 million, G\u0026A expenses of $20.3 million, and a net loss of $111.3 million for the quarter, along with cash position of $1,171.8 million. The disclosure includes both financial results and material business updates regarding clinical trial progress and executive appointments, which are typical components of a quarterly earnings release.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:28:03.132497+00:00","company_name":"Kailera Therapeutics, Inc.","ticker":"KLRA","filing_date":"2026-08-12"}]}